Interleukin-17 (IL-17) Inhibitors Industry Intelligence Report 2026: Target Population, Competitive Landscape, Market Forecast

Prominent pipeline candidates include sonelokimab, izokibep, SFA-002 and simepdekinra, alongside additional therapies in Phase I, Phase II and Phase III development

Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Interleukin-17 (IL-17) Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of the global IL-17 inhibitors market, including historical performance, current treatment practices, patient populations, competitive dynamics and market forecasts from 2022 to 2036. The analysis covers the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.

IL-17 inhibitors have become an important treatment class for chronic immune-mediated inflammatory diseases, particularly plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis and hidradenitis suppurativa. Market expansion is supported by the rising prevalence of autoimmune and inflammatory diseases, increasing physician familiarity with biologic therapies, broader patient access and continued indication expansion.

Key IL-17 Inhibitors Market Highlights

• Leading approved IL-17 inhibitors include BIMZELX (bimekizumab), COSENTYX (secukinumab), TALTZ (ixekizumab) and SILIQ/KYNTHEUM/LUMICEF (brodalumab).
• BIMZELX offers differentiated dual inhibition of IL-17A and IL-17F, supporting its competitive position across multiple dermatology and rheumatology indications.
• Biologic-naive patients generally demonstrate stronger response rates, while patients previously treated with biologics, particularly TNF inhibitors, may present more refractory disease.
• Prominent pipeline candidates include sonelokimab, izokibep, SFA-002 and simepdekinra, alongside additional therapies in Phase I, Phase II and Phase III development.
• New market entrants are expected to increase competition, create pricing pressure and encourage more aggressive payer contracting for formulary access.
• Innovation is increasingly focused on enhanced tissue penetration, greater binding affinity, differentiated cytokine targeting and improved dosing profiles.

Approved and Emerging IL-17 Therapies

BIMZELX, developed by UCB , selectively inhibits IL-17A, IL-17F and IL-17A/F. Its dual-targeting profile represents a significant scientific and commercial differentiator in diseases where both IL-17A and IL-17F contribute to inflammation. The therapy has secured approvals across several dermatology and rheumatology indications, strengthening competition with established products such as COSENTYX and TALTZ.

Brodalumab is marketed as SILIQ in the United States, KYNTHEUM in Europe and LUMICEF in Japan. The therapy targets IL-17 receptor A and is approved for eligible adults with moderate-to-severe plaque psoriasis. Its regional commercialization involves Astrazeneca , Bausch Health, Kyowa Kirin and LEO Pharma.

Sonelokimab, developed by MoonLake Immunotherapeutics, is an investigational tri-specific Nanobody targeting IL-17A/A, IL-17A/F and IL-17F/F dimers. Late-stage development includes hidradenitis suppurativa and psoriatic arthritis, with additional studies in axial spondyloarthritis and palmoplantar pustulosis. In 2026, MoonLake reported regulatory alignment with the US Food and Drug Administration regarding its planned biologics license application for sonelokimab in hidradenitis suppurativa.

Izokibep, developed by Affibody, is a Next -generation IL-17A inhibitor designed for high potency and enhanced tissue penetration. The candidate is progressing through Phase III development, including programs in psoriatic arthritis and hidradenitis suppurativa. Positive clinical data have reinforced its potential to compete with first-generation IL-17 biologics.

SFA-002 is an investigational oral immunomodulator in Phase II development for plaque psoriasis. Its clinical program evaluates activity across multiple inflammatory pathways, including IL-17, IL-23, TNF-?, IFN-? and IL-10.

IL-17 Inhibitors Market Outlook

The IL-17 inhibitors market is expected to maintain strong growth through 2036, driven by expanding use in dermatology and rheumatology, increasing treatment rates and the launch of Next -generation therapies. COSENTYX, TALTZ, SILIQ and BIMZELX currently shape the commercial landscape, while sonelokimab and izokibep could influence future treatment selection and market share.

Competition will increasingly depend on comparative efficacy, safety, speed of response, durability, dosing frequency, route of administration, tissue penetration and access. Payers are also expected to exert greater influence through pricing negotiations, formulary controls and contracting as more products enter the IL-17 inhibitor market.

Report Coverage and Analysis

• Historical and forecasted IL-17 inhibitors market size from 2022 to 2036
• Market share and uptake forecasts for approved and emerging therapies
• Diagnosed, eligible and treated patient populations across selected indications
• Current treatment algorithms, prescribing trends and unmet medical needs
• Phase I, Phase II and Phase III IL-17 inhibitor pipeline analysis
• Drug profiles, clinical trial activity, approvals, patents and collaborations
• Country-level market access, reimbursement and affordability assessments
• SWOT and conjoint analyses of leading approved and pipeline therapies
• Competitive intelligence covering licensing, mergers, acquisitions and partnerships

The report incorporates primary research and insights from key opinion leaders across the 7MM. Experts from major academic and clinical institutions contributed perspectives on treatment patterns, biologic switching, patient acceptance, access barriers, therapy uptake and the evolving competitive environment. These findings support the evaluation of commercial opportunities and unresolved needs within the IL-17 treatment landscape.

Strategic Value of the Report

This IL-17 inhibitors market report enables pharmaceutical companies, biotechnology firms, investors and healthcare stakeholders to assess growth opportunities, benchmark competitors and refine clinical development and commercialization strategies. It also provides visibility into country-specific reimbursement conditions, patient assistance programs, treatment accessibility and the cost burden associated with biologic therapies.

By combining epidemiology, market forecasting, pipeline intelligence, expert perspectives and competitive analysis, the report offers actionable insights into the therapies and indications most likely to shape the IL-17 inhibitors market through 2036.

A selection of companies mentioned in this report includes, but is not limited to:

• MoonLake Immunotherapeutics
• UCB Pharma
• Astrazeneca /Bausch Health/Kyowa Kirin/LEO Pharma
• Affibody Medical AB
• SFA Therapeutics
• DICE Therapeutics/Eli Lilly

For more information about this report visit https://www.researchandmarkets.com/r/2nw6o6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900